February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Emirates Oncology Society – The exploratory biomarker analysis of the Phase 3 KEYNOTE-522 study
Jan 30, 2025, 11:56

Emirates Oncology Society – The exploratory biomarker analysis of the Phase 3 KEYNOTE-522 study

Emirates Oncology Society shared on LinkedIn:

“Join EOS for an insightful session with Dr. Aref Chehal, as he presents the exploratory biomarker analysis of the Phase 3 KEYNOTE-522 study on neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC) during the Best of SABCS UAE!

Date: Saturday, February 8, 2025
Location: Anantara, Downtown Dubai, UAE

Register now!
Find the Registration link in the BIO.

This exclusive event by EOS and Emirates Breast Cancer Working Group!”

Emirates Oncology Society - The exploratory biomarker analysis of the Phase 3 KEYNOTE-522 study